Clinical study to investigate the potential of an engineered human monoclonal antibody, hCTM01, for targeted chemotherapy of ovarian cancer

T.J. Broadhead, Q. Davies, A.C. van Hof, C.F.M. Molthoff, A.C. Perkins, J.C. Roos, W.M. Prinssen, RHM Verheijen, W. Hollander, M. Sopwith, M. Frier, P. Kenemans, E.M. Symonds

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)55-57
JournalTumor Targeting
Volume3
Publication statusPublished - 1998

Cite this